Noël TORDO CANINE ADENOVIRUS- BASED VACCINES AGAINST RABIES working together to stop the ongoing...
-
Upload
jack-schwartz -
Category
Documents
-
view
215 -
download
0
Transcript of Noël TORDO CANINE ADENOVIRUS- BASED VACCINES AGAINST RABIES working together to stop the ongoing...
![Page 1: Noël TORDO CANINE ADENOVIRUS- BASED VACCINES AGAINST RABIES working together to stop the ongoing tragedy of rabies!](https://reader036.fdocuments.us/reader036/viewer/2022062619/55153bd755034685568b4c78/html5/thumbnails/1.jpg)
Noël TORDO
CANINE ADENOVIRUS-BASED VACCINES AGAINST RABIES
working together to stop the ongoing tragedy of rabies!
![Page 2: Noël TORDO CANINE ADENOVIRUS- BASED VACCINES AGAINST RABIES working together to stop the ongoing tragedy of rabies!](https://reader036.fdocuments.us/reader036/viewer/2022062619/55153bd755034685568b4c78/html5/thumbnails/2.jpg)
Institut Pasteur, Paris, FranceUnit Antiviral Strategies
Corinne JALLETNoël TORDO
INRA-AFSSA-ENVA Maisons-Alfort, France UMR1161 - Virologie
Marion SZELECHOWSKIAnnie FOURNIER Bernard KLONJKOWSKIMarc ELOIT
![Page 3: Noël TORDO CANINE ADENOVIRUS- BASED VACCINES AGAINST RABIES working together to stop the ongoing tragedy of rabies!](https://reader036.fdocuments.us/reader036/viewer/2022062619/55153bd755034685568b4c78/html5/thumbnails/3.jpg)
previous papers…
![Page 4: Noël TORDO CANINE ADENOVIRUS- BASED VACCINES AGAINST RABIES working together to stop the ongoing tragedy of rabies!](https://reader036.fdocuments.us/reader036/viewer/2022062619/55153bd755034685568b4c78/html5/thumbnails/4.jpg)
G PV
E10
E3+E1+
left ITR right ITR
E30E10
E1+ E3+
GFP
Replicative Cav2Cav-G R+
Non Replic. Cav2Cav-G R0
Non Replic. HumanAd5-G R0
Replicative Cav2Cav-GFP R+
Wild-type Cav2
Recombinant canine adenovirus (Cav2)
E3+E1+
G PV
E3+
G PV
![Page 5: Noël TORDO CANINE ADENOVIRUS- BASED VACCINES AGAINST RABIES working together to stop the ongoing tragedy of rabies!](https://reader036.fdocuments.us/reader036/viewer/2022062619/55153bd755034685568b4c78/html5/thumbnails/5.jpg)
Ad5-G R0Cav2-G R+Cav2-G R0 Cav2
Ad5G R0
Cav2G R+
Cav2G R0
Cav2Mpurif.G NI
Data.004
100 101 102 103 104
FL1-Height
M1M2
Data.002
100 101 102 103 104
FL1-Height
M1M2
Data.006
100 101 102 103 104
FL1-Height
M1
M2
Data.008
100 101 102 103 104
FL1-Height
M1
M295.68 %531.80
92.44 %396
2.08 %21.26
99.51 %1162.35
Ad5-G R0Cav-G R+Cav-G R0 Cav2
Expression of recombinant Gpv in CHO-CAR cells (24h; 10 TCID50)
Western blotPolyclonal G4846
IF MAb G D1
99.51 %1162.35Flow
cytometry MAb G D1
![Page 6: Noël TORDO CANINE ADENOVIRUS- BASED VACCINES AGAINST RABIES working together to stop the ongoing tragedy of rabies!](https://reader036.fdocuments.us/reader036/viewer/2022062619/55153bd755034685568b4c78/html5/thumbnails/6.jpg)
0 24 48 72 9610 0
10 1
10 2
10 3
10 4
10 5
10 6
10 7
10 8
10 9
10 10
To
tal I
nfe
ctio
us
Un
its/
ml
Hours
DK
DK-E1
293
CRFK
Multiplication of CaV2-derived viruses in various cell lignes (MOI = 1)
DK
0 24 48 72 9610 0
10 1
10 2
10 3
10 4
10 5
10 6
10 7
10 8
10 9
10 10
Hours
To
tal I
nfe
ctio
us
Un
its/
ml
Cav2-GFP R+
Cav2-G R+
Cav2
Hours
DK-E1
To
tal I
nfe
ctio
us
Un
its/
ml
0 24 48 72 9610 0
10 1
10 2
10 3
10 4
10 5
10 6
10 7
10 8
10 9
10 10
Cav2-GFP R+
Cav2-G R+
Cav2
Cav2
dog cells
other cells
![Page 7: Noël TORDO CANINE ADENOVIRUS- BASED VACCINES AGAINST RABIES working together to stop the ongoing tragedy of rabies!](https://reader036.fdocuments.us/reader036/viewer/2022062619/55153bd755034685568b4c78/html5/thumbnails/7.jpg)
I.M. immunization (tibialis muscle) 107 TCID50 Cav2 in 50 l / mouse 27 day (VNAbs) 48 days (VNAbs + T cell response)
Immunogenicity of recombinant Cav2 in C57BL/6 mice by IM route (107 TCID50 )
![Page 8: Noël TORDO CANINE ADENOVIRUS- BASED VACCINES AGAINST RABIES working together to stop the ongoing tragedy of rabies!](https://reader036.fdocuments.us/reader036/viewer/2022062619/55153bd755034685568b4c78/html5/thumbnails/8.jpg)
0
1
2
3
4
5
Pro
lifer
ativ
e In
dex
1
10
100
1000
UI/m
l
Ad5-G R0
Virus Neutralizing Antibodies (VNA) Proliferative Index (G protein)
Cav-G R0 Cav-G R+ Cav2 Ad5-G R0 Cav-G R0 Cav-G R+ Cav2
Immunogenicity of recombinant Cav2 by IM route (107 TCID50 )
individual results
![Page 9: Noël TORDO CANINE ADENOVIRUS- BASED VACCINES AGAINST RABIES working together to stop the ongoing tragedy of rabies!](https://reader036.fdocuments.us/reader036/viewer/2022062619/55153bd755034685568b4c78/html5/thumbnails/9.jpg)
D27 D48
VNA GMT RangeVNA GMT
Range
Ad5-GR0 316,77 101-546 194,35 76-504
Cav-G R0 58,23 47,6-72,3 46,18 23,1-72,4
Cav-G R+ 56,33 44,2-68,9 68,27 52-78
Cav2 0 0
D48
Proliferative index
Range
Ad5-G0 2,23 1,5-3
Cav-G R0 1,94 1,1-2,7
Cav-G R+ 1,98 1,7-4,6
Cav2 1
Immunogenicity of recombinant Cav2 by IM route (107 TCID50 )
Virus Neutralizing Antibodies (VNA) Proliferative Index (G protein)
![Page 10: Noël TORDO CANINE ADENOVIRUS- BASED VACCINES AGAINST RABIES working together to stop the ongoing tragedy of rabies!](https://reader036.fdocuments.us/reader036/viewer/2022062619/55153bd755034685568b4c78/html5/thumbnails/10.jpg)
21 day (VNAbs) 25 day (challenge)
Protection of recombinant Cav2IM (7.106 TCID50 ) or oral (7.107 TCID50 ) routes
7.106 TCID50
7.107 TCID50
![Page 11: Noël TORDO CANINE ADENOVIRUS- BASED VACCINES AGAINST RABIES working together to stop the ongoing tragedy of rabies!](https://reader036.fdocuments.us/reader036/viewer/2022062619/55153bd755034685568b4c78/html5/thumbnails/11.jpg)
Vaccination RouteVNA GMT
(IU)Range Survivors
Cav-G R+ IM 45,28 25-83 9/9
Cav-G R+ oral 1,64 0,38-7,5 7/9
Cav-GFP R+
IM 0 0/5
Cav-GFP R+
oral 0 0/5
Control 0 0/3
0
20
40
60
80
100
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
days post challenge
% s
urv
ival
Cav-G R+ (I.M)
Cav-G R+ (oral)
Cav-GFP R+ (I.M)
Cav-GFP R+ (oral)
Control
Protection of recombinant Cav2IM (7.106 TCID50 ) or oral (7.107 TCID50 ) routes
IM Cav-G R+
OR Cav-G R+
IM Cav-GFP R+
OR Cav-GFP R+
Control
Virus Neutralizing Antibodies (day 21) Challenge (day 25)
![Page 12: Noël TORDO CANINE ADENOVIRUS- BASED VACCINES AGAINST RABIES working together to stop the ongoing tragedy of rabies!](https://reader036.fdocuments.us/reader036/viewer/2022062619/55153bd755034685568b4c78/html5/thumbnails/12.jpg)
Experiments in dogs in progress…
Collaboration with the AFSSA NancyFlorence CLIQUETJacques BARRAT
![Page 13: Noël TORDO CANINE ADENOVIRUS- BASED VACCINES AGAINST RABIES working together to stop the ongoing tragedy of rabies!](https://reader036.fdocuments.us/reader036/viewer/2022062619/55153bd755034685568b4c78/html5/thumbnails/13.jpg)
CONCLUSIONS
•.
Cav2 grow well in canine cell lines and produce significant quantities of recombinant rabies G protein
•.
Canine adenovirus (Cav2) -derived viruses (replicative and non replicative) expressing the rabies (PV strain) G protein have been produced
•.
Cav2 are immunogenic (humoral and cellular responses) by both IM and oral routes
•. Dog experiments are in progress…
•.
IM and oral vaccination of mice with replicative Cav2 G viruses protect them against a peripheral challenge
Cav2 G viruses are promising tools for oral vaccination of dogs
![Page 14: Noël TORDO CANINE ADENOVIRUS- BASED VACCINES AGAINST RABIES working together to stop the ongoing tragedy of rabies!](https://reader036.fdocuments.us/reader036/viewer/2022062619/55153bd755034685568b4c78/html5/thumbnails/14.jpg)